drugset / Trial / NCT01162421
A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
RandomizedParallel-groupOpen-labelTreatment
Summary
A Canadian study to evaluate early use of adalimumab after methotrexate failure in early rheumatoid arthritis. The study hypothesis will verify if adalimumab effectively reduces joint damage in more participants when introduced earlier than in current practice.
Timeline
- Start
- 2010-09
- Primary completion
- 2015-07
- Completion
- 2015-07
Outcome
Missed primary endpoint
registry Standard of Care vs Early Adalimumab; p = 0.907; Difference in percentage -1.3 (95% CI -23.4 to 20.8); Chi-squared NCT01162421 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Background | Methotrexate | Small molecule | — | — |